Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy

John T. Kissel, Koreen L. Burrow, Kottil W Rammohan, Jerry R. Mendell

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy. To determine whether immunosuppressant effects were important in mediating this improvement, we performed immunohistochemical analyses on muscle biopsies obtained at the conclusion of the trial. We studied 33 patients: 12 from the placebo group, nine from the low-dose prednisone group (0.75 mg/kg/d), and 12 from the high-dose group (1.5 mg/kg/d). There was a significant difference in total T cells (CD2+) between the placebo group and both treatment groups. Similarly, the number of CD8+ cytotoxic/suppressor T cells was significantly decreased in both treated groups compared with placebo. The number of muscle fibers focally invaded by lymphocytes was also significantly decreased in the two treated groups compared with controls. There were no differences between the low- and high-dose groups. The numbers of B cells, natural killer cells, CD4+ cells, macrophages, and necrotic muscle fibers were not significantly different in the treated and control groups. This study suggests that prednisone may improve strength in Duchenne muscular dystrophy through primarily immunologic mechanisms involving T lymphocytes.

Original languageEnglish
Pages (from-to)667-672
Number of pages6
JournalNeurology
Volume41
Issue number5
StatePublished - May 1 1991
Externally publishedYes

Fingerprint

Duchenne Muscular Dystrophy
Prednisone
Muscle Cells
Placebos
Biopsy
T-Lymphocytes
Muscles
Immunosuppressive Agents
Natural Killer Cells
B-Lymphocytes
Macrophages
Lymphocytes
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. / Kissel, John T.; Burrow, Koreen L.; Rammohan, Kottil W; Mendell, Jerry R.

In: Neurology, Vol. 41, No. 5, 01.05.1991, p. 667-672.

Research output: Contribution to journalArticle

Kissel, John T. ; Burrow, Koreen L. ; Rammohan, Kottil W ; Mendell, Jerry R. / Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. In: Neurology. 1991 ; Vol. 41, No. 5. pp. 667-672.
@article{38c705ff057c4eaf82692761b36be003,
title = "Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy",
abstract = "A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy. To determine whether immunosuppressant effects were important in mediating this improvement, we performed immunohistochemical analyses on muscle biopsies obtained at the conclusion of the trial. We studied 33 patients: 12 from the placebo group, nine from the low-dose prednisone group (0.75 mg/kg/d), and 12 from the high-dose group (1.5 mg/kg/d). There was a significant difference in total T cells (CD2+) between the placebo group and both treatment groups. Similarly, the number of CD8+ cytotoxic/suppressor T cells was significantly decreased in both treated groups compared with placebo. The number of muscle fibers focally invaded by lymphocytes was also significantly decreased in the two treated groups compared with controls. There were no differences between the low- and high-dose groups. The numbers of B cells, natural killer cells, CD4+ cells, macrophages, and necrotic muscle fibers were not significantly different in the treated and control groups. This study suggests that prednisone may improve strength in Duchenne muscular dystrophy through primarily immunologic mechanisms involving T lymphocytes.",
author = "Kissel, {John T.} and Burrow, {Koreen L.} and Rammohan, {Kottil W} and Mendell, {Jerry R.}",
year = "1991",
month = "5",
day = "1",
language = "English",
volume = "41",
pages = "667--672",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy

AU - Kissel, John T.

AU - Burrow, Koreen L.

AU - Rammohan, Kottil W

AU - Mendell, Jerry R.

PY - 1991/5/1

Y1 - 1991/5/1

N2 - A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy. To determine whether immunosuppressant effects were important in mediating this improvement, we performed immunohistochemical analyses on muscle biopsies obtained at the conclusion of the trial. We studied 33 patients: 12 from the placebo group, nine from the low-dose prednisone group (0.75 mg/kg/d), and 12 from the high-dose group (1.5 mg/kg/d). There was a significant difference in total T cells (CD2+) between the placebo group and both treatment groups. Similarly, the number of CD8+ cytotoxic/suppressor T cells was significantly decreased in both treated groups compared with placebo. The number of muscle fibers focally invaded by lymphocytes was also significantly decreased in the two treated groups compared with controls. There were no differences between the low- and high-dose groups. The numbers of B cells, natural killer cells, CD4+ cells, macrophages, and necrotic muscle fibers were not significantly different in the treated and control groups. This study suggests that prednisone may improve strength in Duchenne muscular dystrophy through primarily immunologic mechanisms involving T lymphocytes.

AB - A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy. To determine whether immunosuppressant effects were important in mediating this improvement, we performed immunohistochemical analyses on muscle biopsies obtained at the conclusion of the trial. We studied 33 patients: 12 from the placebo group, nine from the low-dose prednisone group (0.75 mg/kg/d), and 12 from the high-dose group (1.5 mg/kg/d). There was a significant difference in total T cells (CD2+) between the placebo group and both treatment groups. Similarly, the number of CD8+ cytotoxic/suppressor T cells was significantly decreased in both treated groups compared with placebo. The number of muscle fibers focally invaded by lymphocytes was also significantly decreased in the two treated groups compared with controls. There were no differences between the low- and high-dose groups. The numbers of B cells, natural killer cells, CD4+ cells, macrophages, and necrotic muscle fibers were not significantly different in the treated and control groups. This study suggests that prednisone may improve strength in Duchenne muscular dystrophy through primarily immunologic mechanisms involving T lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=0025904393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025904393&partnerID=8YFLogxK

M3 - Article

C2 - 2027481

AN - SCOPUS:0025904393

VL - 41

SP - 667

EP - 672

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -